- Moderna stock hit a 52-week high of $192.31 intraday on Wednesday.
- CEO Stéphane Bancel stated at Bernstein’s conference that Moderna is an mRNA platform company, not just a Covid vaccine company.
- Chief Development Officer David Berman highlighted oncology and rare disease targets.
- Moderna closed down 0.3% on the day.
- intismeran autogene, a personalized cancer vaccine co-developed with Merck, is a key pipeline asset.
- Positive data from intismeran autogene in August caused Moderna shares to nearly triple in one session.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card